NCT01602393

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Chiesi Farmaceutici S.p.A. · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	CHF 5074 1x	oral tablet, 1x, once a day in the morning for 48 weeks
DRUG	CHF 5074 2x	oral tablet, 2x, once a day in the morning for 48 weeks
DRUG	CHF 5074 3x	oral tablet, 3x, once a day in the morning for 48 weeks

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2012-05-21
• Last updated: 2014-02-06

Locations

5 sites across 2 countries: United States, Italy